Skip to main content

Advertisement

SpringerLink
Log in

Remission in psoriatic arthritis

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory joint disease associated with psoriasis that can lead to joint deformity and disability. PsA has a low likelihood of clinical remission and cure. For a long time, therapeutic options for PsA patients have been unsatisfactory, but the introduction of anti-tumor necrosis factor agents have markedly improved articular and cutaneous signs and symptoms. The efficacy of tumor necrosis factor blockers also raised the bar for treatment goals in PsA. Remission may now be an attainable outcome in the treatment paradigm. At this time, specific tools to define PsA remission are not available. New assessments to define remission must be developed and incorporated into clinical trials and longitudinal registries.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Khan M, Schentag C, Gladman DD: Clinical and radiological changes during psoriatic arthritis disease progression. J Rheumatol 2003, 30: 1022–1026.

    PubMed  Google Scholar 

  2. Sokoll KB, Helliwell PS: Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001, 28: 1842–1846.

    PubMed  CAS  Google Scholar 

  3. Gladman DD: Natural history of psoriatic arthritis. Baillieres Clin Rheumatol 1994, 8: 379–394.

    Article  PubMed  CAS  Google Scholar 

  4. Husted J, Gladman DD, Long JA, Farewell VT: Relationship of the Arthritis Impact Measurement Scales to changes in articular status and functional performance in patients with psoriatic arthritis. J Rheumatol 1996, 23: 1932–1937.

    PubMed  CAS  Google Scholar 

  5. Gladman DD, Hing EN, Schentag CT, Cook RJ: Remission in psoriatic arthritis. J Rheumatol 2001, 28: 1045–1048.

    PubMed  CAS  Google Scholar 

  6. Mease PJ, Goffe BS, Metz J, et al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 29: 385–390.

    Article  Google Scholar 

  7. Antoni CE, Kavanaugh A, Kirkham B, et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005, 52: 1227–1236.

    Article  PubMed  CAS  Google Scholar 

  8. de Vlam K, Lories RJ: Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology 2006, 45: 321–324.

    Article  PubMed  Google Scholar 

  9. Gladman DD, Mease PJ, Ritchlin CT, et al.: Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007, 56: 476–488.

    Article  PubMed  CAS  Google Scholar 

  10. Kavanaugh A, Krueger GG, Beutler A, et al.; IMPACT 2 Study Group: Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007, 66: 498–505.

    Article  PubMed  CAS  Google Scholar 

  11. Kavanaugh A, Fransen J: Defining remission in psoriatic arthritis. Clin Exp Rheumatol 2006, 24(6 Suppl 43): S83–87.

    Google Scholar 

  12. Pinals RS, Masi AT, Larsen RA: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981, 24: 1308–1315.

    Article  PubMed  CAS  Google Scholar 

  13. Mierau M, Schoels M, Gonda G, et al.: Assessing remission in clinical practice. Rheumatology 2007, 46: 975–979.

    Article  PubMed  CAS  Google Scholar 

  14. van der Helm-van Mil AH, Breedveld FC, Huizinga TW: Aspects of early arthritis. Definition of disease states in early arthritis: remission versus minimal disease activity. Arthritis Res Ther 2006, 8: 216–222.

    Article  PubMed  Google Scholar 

  15. Lichtenstein MJ, Pincus T: Rheumatoid arthritis identified in population based cross sectional studies: low prevalence of rheumatoid factor. J Rheumatol 1991, 18: 989–993.

    PubMed  CAS  Google Scholar 

  16. Harrison BJ, Silman AJ, Barrett EM, et al.: Presence of psoriasis does not influence the presentation or short-term outcome of patients with early inflammatory polyarthritis. J Rheumatol 1997, 24: 1744–1749.

    PubMed  CAS  Google Scholar 

  17. Tunn EJ, Bacon PA: Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. Br J Rheumatol 1993, 32: 97–103.

    Article  PubMed  CAS  Google Scholar 

  18. van Aken J, van Dongen H, le Cessie S, et al.: Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study. Ann Rheum Dis 2006, 65: 20–25.

    Article  PubMed  Google Scholar 

  19. Kane D, Stafford L, Bresnihan B, FitzGerald O: A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003, 42: 1460–1468.

    Article  CAS  Google Scholar 

  20. Morgan C, Lunt M, Bunn D, et al.: Five-year outcome of a primary-care-based inception cohort of patients with inflammatory polyarthritis plus psoriasis. Rheumatology (Oxford) 2007, 46: 1819–1823.

    Article  CAS  Google Scholar 

  21. Lindqvist UR, Alenius GM, Husmark T, et al.: The Swedish early psoriatic arthritis register—2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol 2008, 35: 668–673.

    PubMed  Google Scholar 

  22. Fransen J, Antoni C, Mease PJ, et al.: Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006, 65: 1373–1378.

    Article  PubMed  CAS  Google Scholar 

  23. Kaltwasser JP, Nash P, Gladman D, et al.; Treatment of Psoriatic Arthritis Study Group: Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004, 50: 1939–1950.

    Article  PubMed  CAS  Google Scholar 

  24. Lories RJ, Derese I, Luyten FP, de Vlam K: Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment. Clin Exp Rheumatol 2008, 26: 96–102.

    PubMed  CAS  Google Scholar 

  25. Vander Cruyssen B, De Keyser F, Kruithof E, et al.: Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo. Ann Rheum Dis 2007, 66: 138–140.

    Article  Google Scholar 

  26. Husted JA, Gladman DD, Farewell WT, Cook RJ: Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001, 45: 151–158.

    Article  PubMed  CAS  Google Scholar 

  27. Krueger G, Koo J, Lebwohl M, et al.: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001, 137: 280–284.

    PubMed  CAS  Google Scholar 

  28. Leeb BF, Andel I, Sautner J, et al.: The Disease Activity Score in 28 joints in RA and psoriatic arthritis patients. Arthritis Rheum 2007, 57: 256–260.

    Article  PubMed  Google Scholar 

  29. Gladman DD, Inman RD, Cook RJ, et al.: International spondyloarthritis interobserver reliability exercise—the INSPIRE study: I. Assessment of spinal measures. J Rheumatol 2007, 34: 1733–1739.

    PubMed  Google Scholar 

  30. Gladman DD, Inman RD, Cook RJ, et al.: International spondyloarthritis interobserver reliability exercise—the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol 2007, 34: 1740–1745.

    PubMed  Google Scholar 

  31. de Vlam K, Lories RJ, Janssen S: Remission is an achievable goal in the treatment of psoriatic arthritis. Ann Rheum Dis 2007, 66(Suppl2): 415–416.

    Google Scholar 

  32. Elkayam O, Yaron I, Shirazi I, et al.: Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis. Rheumatol Int 2000, 19: 101–105.

    Article  PubMed  CAS  Google Scholar 

  33. Foell D, Kane D, Bresnihan B, et al.: Expression of the proinflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology 2003, 42: 1383–1389.

    Article  PubMed  CAS  Google Scholar 

  34. Gratacós J, Casado E, Real J, Torre-Alonso JC: Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis 2007, 66: 493–497.

    Article  PubMed  Google Scholar 

  35. Mastroianni A, Minutilli E, Mussi A, et al.: Cytokine pro-files during infliximab monotherapy in psoriatic arthritis. Br J Dermatol 2005, 153: 531–536.

    Article  PubMed  CAS  Google Scholar 

  36. Ribbens C, Martin y Porras M, Franchimont N, et al.: Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002, 61: 161–166.

    Article  PubMed  CAS  Google Scholar 

  37. Cordiali-Fei P, Trento E, D’Agosto G, et al.: Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. Ann N Y Acad Sci 2007, 1110: 578–589.

    Article  PubMed  CAS  Google Scholar 

  38. Levene AP, Morgan GJ, Davies FE: The use of genetic microarray analysis to classify and predict prognosis in haematological malignancies. Clin Lab Haematol 2003, 25: 209–220.

    Article  PubMed  CAS  Google Scholar 

  39. Luyten FP, Lories RJ, Verschueren P, et al.: Contemporary concepts of inflammation, damage and repair in rheumatic diseases. Best Pract Res Clin Rheumatol 2006, 20: 829–848.

    Article  PubMed  CAS  Google Scholar 

  40. de Vlam K, Lories RJ, Luyten FP: Mechanisms of pathologic new bone formation. Curr Rheumatol Rep 2006, 8: 332–337.

    Article  PubMed  Google Scholar 

  41. Wang JH, Li Z, Yang G, Khan M: Repetitively stretched tendon fibroblasts produce inflammatory mediators. Clin Orthop Relat Res 2004, (422): 243–250.

    Article  PubMed  Google Scholar 

  42. de Vlam K, Gottlieb AB, FitzGerald O: A review of biological biomarkers in psoriatic disease (GRAPPA 2007). J Rheumatol 2008 (in press).

  43. de Vlam K, Lories RJ, Janssen S: Prediction of time relapse after withdrawal of etanercept in psoriatic arthritis. Ann Rheum Dis 2007, 66(Suppl 2): 416.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000, Leuven, Belgium

    Kurt de Vlam

Authors
  1. Kurt de Vlam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rik J. U. Lories
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kurt de Vlam.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Vlam, K., Lories, R.J.U. Remission in psoriatic arthritis. Curr Rheumatol Rep 10, 297–302 (2008). https://doi.org/10.1007/s11926-008-0048-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-008-0048-z

Keywords

Search

Navigation